Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

Share Price is delayed by 15 minutes
Get Live Data
31.00    0.00 (0.00%)
Bid:
30.00
Ask:
32.00
Spread: 2.00 (6.667%)
Market Cap: £56.06m
IKA Live PriceLast checked at - London Stock Exchange

Intraday Ilika Plc Share Chart

Goliath P1 Cells Validated by Customer Testing

1 May 2025 07:00

RNS Number : 8702G
Ilika plc
01 May 2025
 

Ilika plc

("Ilika", the "Group", or the "Company")

 

Goliath P1 Cells Validated by Customer Testing

 

Ilika (AIM: IKA), an independent global expert in solid-state battery technology, announces that it has received confirmation from OEM and Tier 1 testing partners that its P1 Goliath prototypes perform to specification.

 

Further to its RNS of May 2024 announcing commencement of testing of P1 prototype cells on behalf of, and subsequently by, commercial partners, Ilika confirms that the suite of tests including cell formation protocol, measurement of energy capacity, charge rate, power delivery capability and accelerated cyclability have confirmed the specification of its P1 cells. Furthermore, the tests demonstrated good reproducibility across the batch and delivered the expected electrochemical signature.

 

The tests were carried out under commercial agreements with confidentiality provisions designed to protect proprietary duty cycle protocols owned by the OEMs and Tier 1 companies. The test protocols used are representative of those used to evaluate batteries for electric vehicles and, while the protocols vary from one partner to another, the results have been consistent, and they are globally relevant.

 

The Head of Battery Development at an UK-based electrification Tier 1 supplying global OEMs, stated, "We can confirm that we have completed testing of Ilika's P1 prototypes and they perform to specification, putting them in the cohort of leading solid-state batteries we have tested. We look forward to evaluating further prototypes as Ilika progresses through its roadmap."

 

Graeme Purdy, Ilika CEO, stated, "Customer validation of our Goliath roadmap is of primary importance to us to ensure that we are progressing towards a minimum viable product that meets or exceeds customer expectations. Clearly, this set of validations increases our confidence in the attractiveness of our roadmap. We will continue to engage with a portfolio of potential manufacturing partners to minimise commercialisation risk."

 

In parallel with the validation programmes carried out on its P1s, Ilika has continued to develop its batteries as outlined in its 2024 annual report. In October 2024, Ilika announced compelling safety test data validated by the Faraday Institution's Safebatt programme. Ilika is currently conducting in-house testing of larger 10Ah cells associated with its materials design freeze before releasing its 10Ah (P1.5) prototypes in H2 CY25. Ilika's near-term roadmap extends through to 50Ah minimum viable product (MVP), with the first release expected at the end CY25. Ilika's Goliath MVP, or P2 prototypes, will underpin licensing opportunities.

 

ENDS

 

--

Enquiries:

 

Ilika Plc Graeme Purdy, Chief Executive

Jason Stewart, Chief Financial Officer

 

www.ilika.com

Via FTI Consulting

 

Cavendish Capital Markets Limited (Nomad and Broker) Peter Lynch

Neil McDonald

 

+44 (0)131 220 9772

+44 (0)131 220 9771

 

FTI Consulting (Comms Advisors)

Ben Brewerton

Elizabeth Adams

Dwight Burden

ilika@fticonsulting.com

 

 

About Ilika plc - https://www.ilika.com

 

Ilika is a global expert in the development of solid state battery technology for electric vehicles, medical devices and consumer appliances. The Company's pioneering next-generation technologies aim to provide scalable, affordable alternatives to conventional batteries, to industries which need to incorporate a smaller, lighter, and safer power source in their products.

 

The Company has two product lines. Its Stereax batteries are designed for powering miniature medical implants, industrial wireless sensors and Internet of Things (IoT) applications and the Goliath large format batteries designed for EV cars and cordless appliances.

 

Through its licensing business model, Ilika supplies its IP portfolio to both OEMs and manufacturing partners in exchange for a license fee and future royalties.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFBLFXEZLZBBF
Date   Source Headline
23rd Jun 202111:06 amRNSSecond Price Monitoring Extn
23rd Jun 202111:05 amRNSPrice Monitoring Extension
22nd Jun 20219:02 amRNSPrice Monitoring Extension
21st Jun 20217:00 amRNSTrading Update & Notice of Results
8th Apr 20217:00 amRNSAppointment of Berenberg as Joint Corporate Broker
6th Apr 20217:00 amRNSGoliath manufacturing design collaboration
18th Mar 20217:00 amRNSISO Certification
4th Mar 20215:30 pmRNSHolding(s) in Company
25th Feb 20217:00 amRNSStereax Manufacturing Update
11th Feb 20214:30 pmRNSAward of Share Options
19th Jan 20214:42 pmRNSSecond Price Monitoring Extn
19th Jan 20214:36 pmRNSPrice Monitoring Extension
14th Jan 202111:07 amRNSSecond Price Monitoring Extn
14th Jan 202111:01 amRNSPrice Monitoring Extension
14th Jan 20217:00 amRNSHalf-year Report
12th Jan 20214:37 pmRNSPrice Monitoring Extension
11th Jan 20214:41 pmRNSSecond Price Monitoring Extn
11th Jan 20214:37 pmRNSPrice Monitoring Extension
7th Jan 20214:41 pmRNSSecond Price Monitoring Extn
7th Jan 20214:37 pmRNSPrice Monitoring Extension
6th Jan 20214:42 pmRNSSecond Price Monitoring Extn
6th Jan 20214:39 pmRNSPrice Monitoring Extension
6th Jan 20212:06 pmRNSSecond Price Monitoring Extn
6th Jan 20212:01 pmRNSPrice Monitoring Extension
6th Jan 202111:06 amRNSSecond Price Monitoring Extn
6th Jan 202111:01 amRNSPrice Monitoring Extension
6th Jan 20219:06 amRNSSecond Price Monitoring Extn
6th Jan 20219:00 amRNSPrice Monitoring Extension
29th Dec 20204:36 pmRNSPrice Monitoring Extension
29th Dec 202010:04 amRNSStmnt re Share Price Movement
24th Dec 20201:06 pmRNSHolding(s) in Company
23rd Dec 20204:41 pmRNSSecond Price Monitoring Extn
23rd Dec 20204:36 pmRNSPrice Monitoring Extension
23rd Dec 20202:06 pmRNSSecond Price Monitoring Extn
23rd Dec 20202:01 pmRNSPrice Monitoring Extension
23rd Dec 202011:06 amRNSSecond Price Monitoring Extn
23rd Dec 202011:01 amRNSPrice Monitoring Extension
21st Dec 202010:08 amRNSHolding(s) in Company
9th Dec 202012:42 pmRNSHolding(s) in Company
24th Nov 20205:37 pmRNSHolding(s) in Company
24th Nov 20207:00 amRNSUpdate on Stereax Manufacturing Implementation
11th Nov 20207:00 amRNSTrading Update & Notice of Results
4th Nov 20207:00 amRNSInvestor Webinar
13th Oct 20204:15 pmRNSHolding(s) in Company
23rd Sep 20207:00 amRNSFramework Agreement with UKBIC
22nd Sep 20201:50 pmRNSResult of AGM
26th Aug 20207:00 amRNSStereax® manufacturing plans update
26th Aug 20207:00 amRNSAnnual Report & Notice of AGM
14th Aug 20203:56 pmRNSHolding(s) in Company
14th Aug 20202:06 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.